Lily Lee Email

VP, Head Medical Affairs . TG Therapeutics

Current Roles

Employees:
404
Revenue:
$152k
About
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX".
TG Therapeutics Address
2 Gansevoort Street
New York, NY
United States
TG Therapeutics Email

Past Companies

TG Therapeutics, Inc.Vice President, Head of Medical Affairs
TG Therapeutics, Inc.Executive Director, Disease Area Head, Immunology
Arena Pharmaceuticals, Inc.Senior Director and Medical Value Team Lead, Global Medical Affairs

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.